U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07225504) titled 'A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis' on Nov. 04.
Brief Summary: The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Secondary Progressive Multiple Sclerosis (SPMS)
Intervention:
DRUG: Remibrutinib (blinded)
Remibrutinib (Blinded) active treatment, oral tablet
DRUG: Placebo
Matching placebo (binded), oral tablet
DRUG: Remibrutinib (Open label)
Remibrutinib (Open Label), oral tablet
Recruitment Status...